UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~October 281, 2007

~~ALTEON~~SYNVISTA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-16043	13-3304550
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

221 West Grand Avenue

Montvale, New Jersey 07645

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (201) 934-5000

Not Applicable

___________________________________

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS.

On ~~June 28~~October 1, 2007, ~~Alteon~~Synvista Therapeutics, Inc., a Delaware corporation (the “Company”), announced that itDr. Carl Mendel, MD, has ~~dosed~~joined ~~its~~the ~~first~~Company as its ~~patient~~Vice inPresident aof ~~60-patient~~Clinical ~~Phase~~Development 2and ~~clinical~~Chief ~~trial~~Medical ~~(Study~~Officer, commencing ~~201)~~on October 1, 2007. Dr. Mendel will receive an annual salary of $265,000 and will ~~ALT-2074,~~be ~~its~~eligible ~~lead~~to ~~glutathione~~receive ~~peroxidase~~an ~~mimetic,~~annual incash ~~diabetic~~bonus ~~patients~~based ~~with~~on predetermined milestones aof ~~variant~~up to 20% of ~~haptoglobin~~his ~~that~~annual ~~renders~~salary. ~~them~~In ataddition, ~~high~~upon ~~risk~~commencement ~~for~~of ~~cardiovascular~~his employment ~~complications.~~with ~~This~~the ~~dose~~Company, ~~escalating~~Dr. ~~study~~Mendel iswill ~~designed~~be togranted ~~evaluate~~options ~~ALT-2074’s ability~~ to ~~lower~~purchase ~~inflammatory~~70,000 ~~cardiovascular~~shares of ~~biomarkers~~the inCompany’s ~~patients~~common ~~with~~stock at an ~~elevated~~ ~~risk~~exercise ~~for~~price ~~cardiovascular~~equal ~~events.~~to Athe ~~copy~~closing ofprice of the ~~press~~common ~~release~~stock ison ~~attached hereto~~the asgrant ~~Exhibit~~date. 99Dr.1 ~~and~~Mendel ~~incorporated~~will ~~herein~~be byan ~~reference~~at-will employee of the Company.

~~ITEM~~A 9copy of the press release announcing Dr.01 ~~FINANCIAL~~Mendel’s appointment is attached hereto as ~~STATEMENTS~~Exhibit ~~AND~~99.1 ~~EXHIBITS~~and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d)

Exhibits.

99.1 Press Release dated ~~June~~October 281, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALTEON INC.
	SYNVISTA THERAPEUTICS, INC.
Date: June 28, 2007	By:	/s/ Noah Berkowitz, M.D. , Ph.D.
Dated: October 1, 2007	By:	/s/ Noah Berkowitz, M.D., Ph.D.
		Noah Berkowitz, M.D., Ph.D.
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number

Description

99.1 Press Release dated ~~June~~October 281, 2007.

Filing Compare · Synvista Therapeutics, Inc.